Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial - Concepedia

Concepedia

Publication | Open Access

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial

DOI Full Paper Access

11

Citations

34

References

2023

Year

Xi Zhang, Aparna Gunda, Elma Meershoek‐Klein Kranenbarg, Gerrit‐Jan Liefers, Badada Ananthamurthy Savitha, Payal Shrivastava, Chandra Prakash V Serkad, Taranjot Kaur, Mallikarjuna Siraganahalli Eshwaraiah, Rob A.�E.�M. Tollenaar,

Breast Cancer Research

Abstract

Cost-effective CAB is a statistically robust prognostic and predictive tool for ten-year DM for postmenopausal women with HR+/HER2-, early breast cancer. CAB low-risk patients who received exemestane monotherapy had an excellent ten-year DRFi.

References

	Year	Citations

Page 1